论文部分内容阅读
目的探讨拉米夫定对慢性乙型肝炎患者及慢性 HBs Ag携带者 (As C)的疗效和安全性。方法 2 2 8例患者分 3组 ,治疗一组 (As C患者 ) 5 2例和治疗二组 (慢性乙型肝炎患者 ) 89例给予拉米夫定治疗 (10 0 mg/ d) 5 2周 ,对照组 (慢性乙型肝炎患者 ) 87例给予保肝、降酶、对症等治疗。疗效评估包括症状和体征、肝功能和 HBV复制指标。结果治疗 12周 ,慢性乙型肝炎和 As C组血清 HBV DNA阴转率分别为 91.0 %、88.5 % ,对照组仅为 11.5 % (P<0 .0 1) ;第 5 2周末 ,慢性乙型肝炎和 As C组分别为 82 .7%、87.6% ,而对照组为10 .3 % (P<0 .0 1)。治疗 12周 ,慢性乙型肝炎组血清 HBs Ag阴转率为 13 .5 % ,对照组为 4.6% (P>0 .0 5 )、而第 2 6及 5 2周末 ,慢性乙型肝炎组血清 HBs Ag阴转率分别为 3 6.0 %、3 3 .7% ,对照组分别为 5 .7%、3 .4% (P<0 .0 1)。第 12、2 6及 5 2周末 ,As C组血清 HBs Ag阴转率分别为 3 .8%、5 .8%、3 .8% ,与对照组比较无显著性差异 (P>0 .0 5 )。治疗结束时 ,慢性乙型肝炎组及对照组患者之间的 ALT最终复常率无显著性差异 (91.0 %对 86.2 % ,P>0 .0 5 )。在治疗过程中 ,未发生与研究药物相关的严重副作用。结论用拉米夫定可持久地抑制 HBV的复制和临床改善 ,对活动性的慢性乙型肝炎患?
Objective To investigate the efficacy and safety of lamivudine in patients with chronic hepatitis B and chronic hepatitis C carriers (As C). METHODS: Twenty-eight patients were divided into 3 groups: 52 patients in treatment group (Asc patients) and 89 patients in treatment group II (chronic hepatitis B patients) were treated with lamivudine (10 mg / d) for 5 weeks , 87 cases of control group (patients with chronic hepatitis B) given liver protection, Jiangni, symptomatic treatment. Efficacy assessments include symptoms and signs, liver function and HBV replication markers. Results After 12 weeks of treatment, the seroconversion rates of serum HBV DNA in chronic hepatitis B and As C groups were 91.0% and 88.5%, respectively, while those in the control group were only 11.5% (P <0.01). At the end of Week 52, Hepatitis and As C were 82.7% and 87.6% respectively, while the control group was 10.3% (P <0.01). After 12 weeks of treatment, the serum HBsAg negative conversion rate was 13.5% in the chronic hepatitis B group and 4.6% in the control group (P> 0.05), while in the serum of the chronic hepatitis B group The negative conversion rates of HBs Ag were 3 6.0% and 33.7% in the control group and were 5.7% and 3.4%, respectively (P <0.01). On the 12th, 12th, 6th and 52nd weekends, the negative conversion rate of serum HBsAg in As group was 3. 8%, 5.8% and 3. 8%, respectively, with no significant difference compared with the control group (P> 5). At the end of treatment, there was no significant difference in the final ALT rate between patients with chronic hepatitis B and controls (91.0% versus 86.2%, P> 0.05). There were no serious side effects associated with the study drug during the course of treatment. Conclusions Lamivudine can inhibit HBV replication and clinical improvement permanently, and is active chronic hepatitis B?